share_log
Reuters ·  Apr 25 08:00
Compass Therapeutics Inc. - Top-Line Data Readout for Companion-002, Company's Randomized Phase 2/3 BTC U.S. Study, Is Expected by End of 2024
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment